Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00139789
Status:
COMPLETED
Last Update Posted:
2013-08-30
First Post:
2005-08-29
Brief Title:
A Multicenter Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Multicenter Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a multicenter open-label randomized crossover trial in subjects with MS who were already taking a stable dose of baclofen up to 80 mgday for spasticity The trial was designed to assess subject preference for Kemstro or conventional baclofen At Visit 1 subjects were screened and if qualified were randomly assigned to one of two following treatment sequences Kemstroconventional baclofen or conventional baclofenKemstro
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None